Invitae (NVTAQ) Stock Price

Invitae Corp is primarily active in the healthcare and biotechnology industries.

Invitae Corp's main competitors in the market include other genetic testing companies such as Myriad Genetics, Exact Sciences, and Natera.

Invitae Corp is a leading medical genetics company based in San Francisco, California. Founded in 2010, Invitae is focused on providing genetic information to empower patients and healthcare providers in making informed medical decisions. With a mission to bring comprehensive genetic information into mainstream medical practice, Invitae offers a wide range of genetic tests across various medical specialties. The company has rapidly grown through strategic acquisitions and partnerships, expanding its portfolio and capabilities. Invitae's commitment to innovative genetic testing solutions and its dedication to improving patient outcomes has made it a trusted name in the field of medical genetics.

Invitae Corp has achieved several significant milestones in its journey. The company successfully completed several strategic acquisitions, such as CombiMatrix, Good Start Genetics, and Clear Genetics, which have expanded their genetic testing offerings. Invitae Corp also established numerous partnerships with prominent organizations, including Biogen, Bristol Myers Squibb, and Genome Medical, to advance precision medicine research and development. Additionally, they launched a groundbreaking genetic testing platform, enabling fast and affordable genetic testing solutions. Invitae Corp's accomplishments signify their commitment to revolutionizing genetic testing and personalized medicine, positioning them as a key player in the industry.

Invitae Corp is primarily present in the United States.

Invitae Corp is guided by a set of core values and a strong corporate philosophy. The company is committed to providing high-quality genetic information to individuals, families, and healthcare providers. With a focus on patients and their needs, Invitae Corp aims to make genetic testing more accessible and affordable. They strive to deliver accurate results and ensure the information is understandable and actionable for all stakeholders. Invitae Corp also emphasizes collaboration and partnerships within the medical community to advance genetic knowledge and improve patient care. Through these values and their dedication to genetic information, Invitae Corp strives to empower people with the insights to make informed healthcare decisions.

15 analysts currently rate the Invitae stock: 0 recommend buying, 6 holding and 9 selling. For 2026, analysts expect Invitae to generate revenue of 614.60 M USD and earnings per share of -0.90 USD.

Invitae Analyst Price Targets 2026

Converted at the current exchange rate, the Invitae share trades at 0.00 EUR (0.00 USD).

The Invitae share (NVTAQ) is listed on 7 stock exchanges, including: NYSE (NVTA), London (0JDB.L), SIX (Zürich) (IV8.SW), Frankfurt (IV8.F), München (IV8.MU), Düsseldorf (IV8.DU).

Invitae Corp is a company specialized in providing genetic tests. Its business model consists of offering customers accurate insights into their DNA and helping them identify genetic risks or predispositions in order to make better health-related decisions. The company has a specialized laboratory that performs and analyzes genetic tests. Invitae conducts tests in various areas, such as oncology, neurology, and rare diseases. The company also offers a wide range of tests, ranging from preventive screenings to targeted diagnostic tests. To offer these tests, Invitae has built a platform that makes it easy to order genetic tests. Customers can order a test directly from home without needing a referral from a doctor. Patients can order either directly through Invitae's website or through a doctor if they prefer. The company also offers various products such as the "Invitae Carrier Screening," which investigates the transmission of genetic diseases from parents to their children. These tests can also help identify couples at high risk, optimize their genetic counseling, and assist them in family planning. Invitae also provides solutions for customers who have already undergone genetic tests and want to have their results analyzed. The company has developed specialized services that allow combining the results of different tests to provide customers with a comprehensive range of information. The company also partners with various companies and organizations to promote and sell its products and services. Its partners include major hospital systems, laboratories, and insurance companies. Invitae Corp focuses on offering genetic tests in multiple areas to maximize the benefits of genetic technology for patients. It has built an e-commerce platform that makes it easy for customers to order its products. Invitae also offers a wide range of tests covering various applications. With its innovative and comprehensive services, Invitae Corp has established itself as a leading company in the genetics industry.

The expected revenue of Invitae is 614.60 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Invitae is -247.87 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Invitae is currently -0.00. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Invitae stock.

The price-to-sales ratio (P/S) of Invitae is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Invitae stock.

The Eulerpool Quality Score for Invitae is 6/10.

The ISIN of Invitae is US46185L1035. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Invitae is A14NKG. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Invitae is NVTAQ. The ticker symbol is used to trade Invitae shares on the stock exchange.